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Abstract
Background: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may
benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency
ablation. For patients not eligible for such options, prognosis is poor. Sorafenib and Selective Internal Radiation
Therapy (SIRT) are clinically proven treatment options in patients with unresectable HCC, and this study aims to
assess overall survival following either SIRT or Sorafenib therapy for locally advanced HCC patients.
Methods: This investigator-initiated, multi-centre, open-label, randomized, controlled trial will enrol 360 patients
with locally advanced HCC, as defined by Barcelona Clinic Liver Cancer stage B or stage C, without distant
metastases, and which is not amenable to immediate curative treatment. Exclusion criteria include previous
systemic therapy, metastatic disease, complete occlusion of the main portal vein, or a Child-Pugh score of >7.
Eligible patients will be randomised 1:1 and stratified by centre and presence or absence of portal vein thrombosis
to receive either a single administration of SIRT using yttrium-90 resin microspheres (SIR-Spheres®, Sirtex Medical
Limited, Sydney, Australia) targeted at HCC in the liver by the trans-arterial route or continuous oral Sorafenib
(Nexavar®, Bayer Pharma AG, Berlin, Germany) at a dose of 400 mg twice daily until disease progression, no further
response, complete regression or unacceptable toxicity. Patients for both the Sorafenib and SIRT arms will be
followed-up every 4 weeks for the first 3 months and 12 weekly thereafter. Overall survival is the primary endpoint,
assessed for the intention-to-treat population. Secondary endpoints are tumour response rate, time-to-tumour
progression, progression free survival, quality of life and down-staging to receive potentially curative therapy.
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Discussion: Definitive data comparing these two therapies will help to determine clinical practice in the large
group of patients with locally advanced HCC and improve outcomes for such patients.
Trial registration: ClinicalTrials.gov identifier, NCT01135056, first received 24, May 2010.
Keywords: Advanced hepatocellular carcinoma, Liver cancer, Radioembolisation, Selective internal radiation
therapy, SIR-Spheres, Sorafenib, Systemic therapy, Asia-Pacific, Randomized controlled trial, Phase III
Background
The incidence and prevalence of hepatocellular carcinoma
(HCC) is highly variable in different regions of the world,
but the burden is predicted to increase in future years [1].
Approximately 70–80 % of all cases of HCC occur in Asia
where it is an important public health concern [2]. Al-
though around 20 % of patients diagnosed with early stage
HCC may benefit from potentially curative ablative therap-
ies, such as surgical resection, liver transplantation or radio-
frequency ablation [3–5], most patients are diagnosed at an
intermediate to advanced stage of HCC, when treatment
options are limited and the prognosis poor [6, 7]. In pa-
tients with untreated advanced HCC median survival time
is approximately 5–7 months, although this varies depend-
ing on the Child‐Pugh score [8–10].
The only systemic therapy shown to confer survival ad-
vantage in patients with unresectable advanced HCC is
Sorafenib (Nexavar®, Bayer Pharma AG, Berlin, Germany)
[11–13]. In the pivotal Sorafenib Hepatocellular Carcin-
oma Assessment Randomized Protocol (SHARP) trial in
patients with advanced HCC, Sorafenib treatment signifi-
cantly increased median overall survival (OS) by
2.8 months versus placebo (10.7 months versus
7.9 months, respectively; p < 0.001) [6]. A subsequent ran-
domised controlled trial in the Asia-Pacific region con-
firmed these findings, showing median OS of 6.5 months
with Sorafenib treatment versus 4.2 months with placebo
(p < 0.014) [13]. As a result of these data, Sorafenib is the
current recommended first-line treatment for advanced
(Barcelona Clinic Liver Cancer [BCLC] stage C) HCC [2].
Effective systemic therapy is an important option for the
treatment of HCC in the subset of patients with extrahe-
patic metastases and Sorafenib resulted in a median OS of
5.7 months in this group [14]. However, the relative benefits
of Sorafenib and loco-regional ablative therapy are unclear
in the larger group of patients with locally advanced HCC.
This is of critical importance since HCC is a fast-growing
locally aggressive disease frequently leading to the patient’s
death before extrahepatic metastases have developed. Con-
sequently, the response of loco-regional disease to first-line
therapy determines survival in these patients.
Selective Internal Radiation Therapy (SIRT) with
yttrium-90 (Y-90) resin microspheres (SIR-Spheres®;
Sirtex Medical Limited, Sydney, Australia), is one poten-
tial alternative treatment for locally advanced HCC.
SIRT enables targeted delivery of radiation to the tu-
mours, while largely sparing the surrounding liver par-
enchyma. A meta‐analysis showed a high response rate
to Y-90 SIRT in HCC patients [15]. Population disparity
prevented assessment of OS in this meta-analysis, but
cohort studies of patients with HCC receiving SIRT re-
port median OS between 7.0 and 26.3 months [16–25].
Small-scale, retrospective studies have compared SIRT
with Y-90 resin microspheres and Sorafenib, and suggest
similar median OS in patients with BCLC stage B or C
disease [24, 26, 27], and there are some indications that
in patients with locally advanced HCC and portal vein
thrombosis (PVT), SIRT is particularly beneficial [14, 22,
27–29].
However, larger-scale studies are needed to assess this
comparison, and therefore, the Selective Internal Radi-
ation Therapy versus sorafeNIB (SIRveNIB) trial has
been designed as a prospective, randomized, open-label,
multicentre trial to compare median OS in patients with
locally advanced HCC receiving either SIRT with Y-90
resin microspheres or Sorafenib.
Another large-scale comparative study of similar de-
sign in patients with advanced HCC, SorAfenib versus
Radioembolisation in Advanced Hepatocellular carcin-
oma (SARAH), is ongoing in Europe [30], and these two
studies could potentially be combined in a future meta-
analysis.
Methods/Design
Ethics
The SIRveNIB trial will be conducted in accordance with
the Declaration of Helsinki and current Good Clinical
Practice guidelines, and all participating centres will have
obtained the relevant ethics committee approval before
patient enrolment.
Eligible population
The inclusion and exclusion criteria for the SIRveNIB
trial are summarised in Table 1. Informed consent will
be obtained from each participant.
Overview of trial design
SIRveNIB is a prospective, randomized open-label, mul-
ticentre trial comparing SIRT and Sorafenib in patients
with locally advanced HCC. In SIRveNIB, the aim will be
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to recruit a minimum of 360 patients from a minimum
of 15 sites across the Asia-Pacific region.
Eligible patients will be randomized 1:1 to receive ei-
ther systemic therapy with oral Sorafenib or a session of
SIRT with SIR-Spheres® (Fig. 1). Randomisation will be
stratified by centre and the absence or presence of PVT.
Treatment
Treatment in the Sorafenib arm will commence within
1 week after randomisation. Patients will receive oral So-
rafenib, 400 mg twice daily. Sorafenib treatment will be
continued until there is evidence of treatment failure
(lack of efficacy resulting in tumour progression at any
site determined by CT or MRI scan); there is a cure or
complete response and/or the patient undergoes surgical
resection, liver transplantation or ablative therapy; un-
acceptable toxicity occurs; or the patient requests an end
to treatment. As published previously, doses may be de-
layed and/or reduced for clinically significant haemato-
logical toxicities and other toxicities or adverse events
(AEs) related to study therapy. Dose reductions first to
400 mg/day and then to 400 mg every second day will be
allowed, and if further dose reductions are required the pa-
tient should be discontinued. For non-haematological
AEs other than skin toxicity, treatment will be inter-
rupted for any grade 3 AE, and the dose subsequently
reduced by one level. For skin toxicity, treatment will
be interrupted for any grade 2 or grade 3 AE and a de-
creased dose frequency or level will be subsequently
considered. The dose may be re-escalated once the tox-
icities or AEs have resolved [31].
Patients randomised to SIRT will receive SIR-
Spheres at the patient-specific prescribed activity
within 35 days after signing of informed consent
form, and after the baseline assessment of their suit-
ability for the procedure. The assessment comprises a
hepatic angiogram, and a liver-to-lung shunt pre-
assessment with Technetium-99 m (99mTc)-labelled
human serum albumin. The hepatic angiogram will
determine the vascular anatomy of the liver in order
to plan the optimal delivery of the SIR-Spheres. The
99mTc lung-shunt study will assess the presence and
degree of lung shunting from the liver. Patients ran-
domised to SIRT, but who are found to be unsuitable
for treatment will be included in the SIRT intention
to treat analysis. The prescribed activity of SIR-
Spheres® will be calculated based on the patient’s
body surface area (BSA) model [32], or the partition
model [33]. If the BSA method is used for dose cal-
culation and the percentage lung shunting exceeds
20 % of the hepatic artery blood flow, as determined
by 99m Tc-scan, the partition model may be used to
adjust the prescribed activity so that the radiation
absorbed dose to the lungs does not exceed 20 Gy.
Table 1 Patient eligibility criteria for SIRveNIB trial
Inclusion criteria Exclusion criteria
• Unequivocal diganosis of locally advanced HCC without extrahepatic
metastases
• Written informed consent provided
• Aged ≥18 years
• Patients with HCC that is not amenable to surgical resection, immediate
liver transplantation, or that could be treated with local ablative
techniques (e.g. radiofrequency ablation)
• Locally advanced HCC as defined by BCLC (B) intermediate stage or
BCLC (C) advanced stage
• At least one lesion that can be accurately measured in at least one
dimension (longest diameter to be recorded) as ≥10 mm with spiral CT
scan or MRI
• ECOG performance status 0–1
• Adequate haematological function: haemoglobin ≥9.5 g/dl, leukocytes
≥2500/mm3, platelets ≥80,000/mm3, INR ≤2.0
• Adequate kidney function: creatinine <2.0 mg/dl
• Adequate hepatic function: albumin ≥2.5 g/dl, bilirubin ≤2 mg/dl; ALP,
AST or ALT ≤5 x ULN
• Liver cirrhosis Child-Pugh A–B (up to 7 points)
• Life expectancy of at least 3 months without active treatment
• Patients who have had >2 administrations of hepatic artery directed
therapy
• Hepatic artery directed therapy <4 weeks before study entry
• Systemic chemotherapy for HCC, except previous adjuvant or
neoadjuvant therapy given >6 months before enrollment
• Previous treatment with Sorafenib or VEGF inhibitors
• Previous radiotherapy for HCC or other malignancy
• Intractable ascites, or other clinical signs of liver failure
• Complete thrombosis of the main portal vein
• Extrahepatic metastases, except lung nodules <1 cm or local-regional
lymph nodes <2 cm in greatest diameter
• Clinical signs of central nervous system metastases
• Other concurrent malignancy, except for adequately treated basal cell
or squamous cell skin cancer, in situ cervical cancer, or other cancer for
which the patient has been disease free for ≥5 years
• Uncontrolled intercurrent illness
• Contraindications angiograghy to hepatic artery catheterisation: severe
peripheral arterial disease precluding catheterisation, bleeding diathesis
not correctable by standard forms of therapy, portal hypertension with
hepato-fugal flow
• History of allergy to SIR-spheres, Soranefib or related agents
• Patient unable or unwilling to understand or sign the written informed
consent
• Currently enrolled in another investigational therapeutic drug or device
study
• Women, unless postmenopausal or surgically sterile are unwilling to
practice effective contraception
• Men unwilling to use effective contraception during the course of the
study
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate transaminase, CT computed tomography, MRI Magnetic resonance imaging, ECOG Eastern
Cooperative Oncology Group, HCC hepatocellular carcinoma, INR international normalised ratio, ULN upper limit of normal
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Assessments
A quadriphasic contrast-enhanced spiral CT scan of the
abdomen/pelvis will be performed at screening to diag-
nose HCC according to the American Association for
the Study of Liver Diseases (AASLD) criteria [34], deter-
mine the extent of liver disease and to exclude extra-
hepatic abdominal or pelvic metastases. A biopsy posi-
tive for HCC is required for diagnosis if the tumour does
not fulfil the AASLD radiological criteria. A thoracic CT
scan will be performed to exclude lung metastases. MRI
scans will be used in lieu of CT scans in patients for
whom CT scanning is not clinically feasible. Each of
these CT series will be performed less than 28 days be-
fore informed consent is received. All radiology images
in this trial will be centrally reviewed by treatment-
blinded radiologists at the National Cancer Center
Singapore.
All patients will be assessed by the schedule sum-
marised in Table 2. Assessments are at 4-week intervals
for the first three months, and then 12-week intervals
thereafter. After study conclusion patients will be
followed for survival or death at 12-week intervals.
Study conclusion is defined as disease progression,
death, complete regression, unacceptable toxicity, patient-
undergoing surgical resection, liver transplantation or ab-
lative therapy due to a sufficient response with therapy,
loss to follow-up, or patient’s request for withdrawal.
Outcome measures
The primary endpoint of the SIRveNIB trial is overall sur-
vival (OS). Secondary endpoints include: time to progres-
sion (TTP), progression-free survival (PFS), overall and in
the liver; tumour response rate (assessed by Response
Evaluation Criteria in Solid Tumours [RECIST] version 1.1)
[35]; disease control rate; health-related quality of life
(HRQoL); safety and toxicity; and liver resection rate and
liver transplantation rate.
Outcome definitions
 OS – the time from the date of randomisation to
death from any cause.
 TTP – the time from the date of randomisation to
tumour progression at any site in the body.
 PFS at any site – time from the date of
randomisation to tumour progression at any site in
the body or death, whichever is earlier.
 PFS in the liver –time from the date of
randomisation to tumour progression in the liver or
death whichever is earlier.
 Tumour response rate is the number of patients
whose best overall response rate (best tumour
response over the whole study between
randomisation and the last tumour assessment) is
partial response (PR) or complete response (CR),
divided by the total number of patients in the
analysis population.
 Disease control rate – the number of patients whose
best overall response is PR, CR or stable disease
(SD), divided by the total number of patients in the
analysis population.
 HRQoL assessed using the EQ-5D questionnaire.
 Adverse events will be reported according to
National Cancer Institute criteria (National Cancer
Institute Common Terminology criteria for Adverse
Events [NCI CTCAE] Version 4.02) [36].
Sample size calculation and statistical considerations
Based on OS data reported by Kang et al. 2008 and by
Sangro et al. 2010 [14, 37], in patients with locally ad-
vanced HCC median survival times of 9.35 months for
Fig. 1 Overview of the SIRveNIB trial design. ECOG, Eastern Cooperative Oncology Group; PVT, portal vein thrombosis
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Table 2 SIRveNIB trial assessment schedule
Schedule Screening/
Baseline
(Eligibility)
Randomisationa
During Protocol Therapy Study
Conclusion
Post Study
Conclusion
Follow-Up
Week
2b
Week
4
Week
8
Week
12
12-weekly
thereafter
As appropriatec 12 weekly
Informed consent X
Demographics X
Medical and surgical history X
Concurrent illness X
Concomitant medications Xd Xd Xd Xd Xd Xd Xd
Clinical assessment & physical
examination
• Height (Baseline only)
• Weight
• Blood pressure
• Body temperature
X X X X X X
Performance status
• ECOG
X X X X X X
Haematology
• Leukocytes
• Platelets
• Haemoglobin
• INR
X X X X X X
Hepatitis serology
• Hep Bsag
• Anti-HCV IgG
• Hep B Core Antibody
IgG (optional)
Xe
Renal function
• Creatinine
X X X X X X
Liver function
• AST/ALT
• ALP
• Total bilirubin
• Albumin
X X X X X X
Pregnancy test
(as appropriate)
Xf
Tumour marker
• Serum AFP
X X X X
EQ-5D HRQoL X X X X X X X
CT or MRI scan: chest/
abdomen/pelvish, i
X X X
SIRT-arm ONLY
• Hepatic angiogram
• 99mTc- MAA lung
shunt study
X g
Response assessment X X X
Sorafenib arm ONLY
• Toxicity assessment
• Dose delay/modification
Xb X X X X X
Gandhi et al. BMC Cancer  (2016) 16:856 Page 5 of 9
Sorafenib-treated patients and 14 months for patients
treated with Y-90 microspheres are assumed. This repre-
sents the minimum clinically meaningful difference to
be detected.
Group-sequential methods are used to determine the
sample size and study duration. Two interim analyses
and a final analysis are planned to occur at equally
spaced intervals after one-third, two-thirds and all of the
planned number of deaths (events) have been reported.
The planned sample size is determined assuming the use
of a 2-sided log rank test with type I error of 0.05 and
statistical power of 90 %. A dropout rate of up to 20 % is
also factored into the computations. The anticipated
study duration is 5 years; with 3 years of accrual and
2 years follow-up. This corresponds to an estimated haz-
ard rate of 0.67 with an expected 266 deaths at the end
of the study
The number of patients required for randomisation to
detect a clinically relevant difference in OS time with
SIRT versus Sorafenib was determined to be 360 patients
(180 patients in each treatment arm).
Interim analyses
Interim analyses for efficacy are planned after 33 and
65 % of the information (corresponding to 87/266 and
174/266 deaths) have been observed and using a critical
p-value of p ≤ 0.0001 for the first analysis and p ≤ 0.015
for the second analysis These boundaries are obtained
using the method of Lan and DeMets [38] and based on
an overall significance level of 5 %. The final analysis will
be performed after 266 reported deaths.
An independent Data Monitoring Committee will re-
view the safety of the study and the results of the interim
analyses and make appropriate recommendations to the
trial steering committee. .
Statistical analyses
All analyses will be performed using the intention-to-
treat (ITT) principle where patients will be analysed ac-
cording to their randomised group. The analysis of the
primary outcome (OS) will be an unadjusted log rank
test used to test and a proportional hazards model will
be use to estimate the hazard ratio together with the
corresponding 95 % confidence intervals (CI). Time to
event curves (for OS and PFS) will be displayed using
the method of Kaplan-Meier.
The tumour response rate, disease control rate and the
rate of down-staging to surgical resection, radiofrequency
ablation or liver transplantation compared between treat-
ments using appropriate tests for proportions
HRQoL will be analysed using generalised estimating
equations assuming a common (exchangeable/compound
symmetric) correlation structure, following the guidelines
of the EQ-5D questionnaire.
A Landmark analysis will be performed at 2-months
post-randomization comparing patients classified into
four groups: Those randomised to Sorafenib and (i) but
did not receive 80 % of scheduled dose since
randomization; (ii) those receiving at least 80 % of the
scheduled dose; and, those randomized to SIRT therapy
and (iii) did not receive the therapy; (iv) those who re-
ceiving the SIRT therapy within the first two months of
randomization [39]. This analysis will be repeated using
40 and 60 % scheduled doses since randomization for
defining groups (i) and (ii). These comparisons will be
performed for the primary and secondary outcomes.
Patients who died or discontinued the study before 2-
months of randomization will not be included from the
analysis. Additional sub-group analyses will be per-
formed based on patients’ baseline characteristics such
as presence or absence of portal vein thrombosis, BCLC
Table 2 SIRveNIB trial assessment schedule (Continued)
AE/SAE AE/SAE for the Sorafenib arm will be recorded from the time of signing the ICF until 30 days after
the final dose of Sorafenib, or until commencement of the next alternative therapy, whichever is
earlier.
AE/SAE for the SIRT arm will be recorded from the time of signing the ICF until 30 days post-SIRT
regardless of causality and for a further 5 months thereafter if judged by the investigator to be
causally related to SIRT or Sir-Spheres, or until commencement of the next alternative therapy,
whichever is earlier.
If the AE/SAE is a Sorafenib or SIRT related toxicity follow-up will continue until resolution.
Survival X
aScreening assessments performed within 28 days before signing of informed consent can be used to confirm eligibility
bSorafenib arm only. Sorafenib patients contacted at Week 2 to assess treatment related toxicity and interrupt/modify the dose as necessary
cDisease progression, death, complete regression, unacceptable toxicity, patient responds to treatment and becomes eligible for surgical resection, liver
transplantation or ablative therapy, lost to follow-up, patient’s request for withdrawal
dConcomitant medication to be recorded from screening up to 30 days post-study conclusion, or until commencement of the next alternative therapy, whichever
is earlier
eIf either the Hepatitis B Surface Antigen (Hep Bsag) test or anti-HCV IgG test is positive, the other test will be optional. Hepatitis B Core Antibody IgG test
is optional
fWomen of reproductive potential must have a negative pregnancy test before commencing treatment. Test to be repeated if pregnancy is suspected during
the study
gHepatic angiogram and 99mTc-MAA lung shunt study to be performed after randomisation and prior to treatment commencement only for SIRT arm group
hThe same radiological assessment method must be used throughout the study
i Assessment for tumour response rate to be done every 12 weeks from date of randomisation until first evidence of disease progression
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stage, prior HCC treatment, hepatitis status, ECOG per-
formance status, tumour size (≤50 % of liver, > 50 % of
liver), age (<65 years, ≥65 year), and gender.
As the SIRT therapy is a local treatment, treatment ef-
fect of progression in the liver as the first event will be in-
vestigated using a competing risk analysis. In this analysis
death or progression outside the liver as the first event will
be considered as a competing risk for liver progression.
The method of Gray [40] will be used to compare groups
with hazard ratios and 95 % CI estimated from the pro-
portional hazards approach detailed by Fine and Gray
[41]. Time to liver progression in the two groups will be
displayed using cumulative incidence curves.
Toxicity will be reported according to NCI CTCAE
Version 4.02 criteria.
Discussion
The SIRveNIB trial will compare the efficacy and safety
of SIRT with yttrium-90 resin microspheres with that of
Sorafenib in the treatment of locally advanced HCC. To
the authors’ knowledge, no prospective, randomized
controlled trials have been published comparing these
treatment modalities in this patient population. Another
study of similar design is ongoing in a European popula-
tion, where the aetiology of HCC is different from that
of the Asia-Pacific [30].
Sorafenib has been chosen as the control in the SIRve-
NIB trial as the current most effective systemic treat-
ment for patients with unresectable advanced HCC,
SIRT with resin microspheres has also demonstrated
efficacy in advanced HCC [14, 22, 28, 42, 43].
In the SIRveNIB trial, OS has been chosen as the pri-
mary endpoint as it is a more robust measure than PFS,
and the SHARP trial demonstrated the efficacy of Soraf-
enib based on this criterion. Moreover, the kinetics of
tumour progression, as assessed from imaging tech-
niques, is different between SIRT and Sorafenib, render-
ing OS the best option for comparison between arms in
this trial. A European study with similar inclusion cri-
teria is currently ongoing that compares Sorafenib with
SIRT in patients with advanced HCC [30], and could be
used for meta-analysis in the future.
In addition to efficacy analyses, the SIRveNIB trial en-
ables comparison of the toxicity caused by Sorafenib ver-
sus SIRT in patients with locally advanced HCC. This is
important as the cardiovascular toxicity of Sorafenib has
been highlighted in a meta-analysis of cancer patients
(predominantly renal carcinoma) [44], but was not a
common complication in the SHARP study [12].
Limitations to the SIRveNIB study design have been
addressed where feasible. While blinding is not possible
due to the treatment methods, the potential biases
caused by the lack of blinding have been minimised by
the choice of OS as a robust primary endpoint.
The results from the SIRveNIB trial will impact clinical
practice. A definitive randomised controlled trial com-
paring the two most promising therapies in locally-
advanced HCC should help determine the optimal treat-
ment modality in this indication, or may help identify
populations that are best suited to either therapy. In
addition, the data generated from this study will deter-
mine the role of SIRT in in future consensus guidelines.
The study will also pave the way for future trials in com-
bined modality therapies in HCC.
Trial status
The SIRveNIB trial is currently ongoing. Patient recruit-
ment closed on 25 May 2016 with a total of 360 partici-
pants randomised. The final analysis will be triggered
after mortality reaches 266.
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Indonesia (Ref No: 465/PT02.FK/ETIK/2010), Research and Development Unit,
Medical Faculty University of Udayana/Sanglah Hospital Denpasar in
Indonesia (Ref No: 605/Skrt/IX/2010), Asan Medical Centre in South Korea
(Ref No: 2011–0155), Korea University Anam Hospital (Ref No: ED10274),
Seoul National University Hospital (Ref No: E-1102/059-007), The Catholic Uni-
versity of Korea Seoul St. Mary’s Hospital (Ref No: KC11EIGT0112), Yonsei Uni-
versity Health System, Severance Hospital, Institutional Review Board in
South Korea (Ref No: 4-2010-0696), Joint Penang Independent Ethics Com-
mittee (JPEC) in Malaysia (Ref No:11–0026), Medical Ethics Committee Univer-
sity Malaya Medical Center in Malaysia (MECID No: 20149–541), Medical
Ethics Committee of Ministry of Health, Mongolia (No 1), Institutional Review
Board Yangon GI and Liver Center in Myanmar (Ref No: N.A.), Northern Y Re-
gional Ethics Committee in New Zealand (Ref No: NTY/10/06/057/AM05), In-
stitutional Ethics Review Committee St. Luke’s Medical Center in Philippines
(CT Tracking No: CT10012), Institutional Review Board The Medical City in
Philippines (Ref No: N.A.), Makati Medical Center Institutional Review Board
(Ref No: MMCIRB 2011–002), Davao Doctors Hospital Institutional Ethics Re-
view Board (Ref No: N.A.), National Healthcare Group Domain-Specific Review
Board (DSRB) in Singapore for (National University Hospital and Khoo Teck
Puat Hospital) (DSRB Ref No: B/10/337), Institutional Review Board Taipei Vet-
erans General Hospital in Taiwan (Ref No: 201012006MA), Research Ethics
Committee B of the National Taiwan University Hospital (NTUH-REC No:
201010001D), Research Ethics Committee China Medical University & Hospital
in Taiwan (Protocol No./CMUH REC No.: AHCC06/DMR101-IRB1-280), Chang
Gung Memorial Hospital in Taiwan (CGMF Case No.: 103-1622C (Original 99-
2583A)), Committee on Human Rights Related to Research Involving Human
Subject Chulabhorn Hospital in Thailand (Project No:15/2555) Patients giving
consent for participation sign the ethically approved patient informed
consent.
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